EFPIA concerned over SPC waiver amendments

30-11-2018

EFPIA concerned over SPC waiver amendments

GwenGoat / iStockphoto.com

Proposed amendments to the EU’s supplementary protection certificate (SPC) manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).


European Federation of Pharmaceutical Industries and Associations, supplementary protection certificate, European Commission, manufacturing waiver, generic

LSIPR